Shukra Pharmaceuticals Limited (BOM:524632)

Market Cap	18.25B +127.6%
Revenue (ttm)	748.59M +91.9%
Net Income	339.87M +235.9%
EPS	0.81 +262.4%
Shares Out	439.61M
PE Ratio	51.35
Forward PE	n/a
Dividend	0.01 (0.02%)
Ex-Dividend Date	Sep 18, 2025

Volume	733,005
Open	43.50
Previous Close	41.43
Day's Range	41.30 - 43.99
52-Week Range	17.06 - 65.26
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Shukra Pharmaceuticals

Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin ...

• Industry: Pharmaceutical Preparations
• Founded: 1993
• Employees: 115
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524632

Financial Performance

In fiscal year 2026, Shukra Pharmaceuticals's revenue was 567.27 million, an increase of 74.08% compared to the previous year's 325.87 million. Earnings were 220.58 million, an increase of 130.37%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 17, 2026

Data Sources Report a data error